Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABVC BioPharmaABVC -6.85%29 Buyback Yield % is 0.00 as of Aug. 10, 2026. GuruFocus rates ABVC with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 725 Biotechnology companies, ABVC BioPharma ranks worse than 137930.9% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for ABVC BioPharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC vs SGMO, SER, PLRZ: Buyback Yield % Comparison
For the Biotechnology subindustry, ABVC BioPharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC BioPharma (ABVC) has a Buyback Yield % of 0.00 as of Aug. 10, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ABVC BioPharma and its competitors. According to the industry distribution chart, ABVC BioPharma ranks #999999 out of 725 companies in the Biotechnology industry.
Is ABVC BioPharma's Buyback Yield % too high?
ABVC BioPharma's current Buyback Yield % is 0.00. Based on the distribution chart, ABVC BioPharma ranks #999999 out of 725 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ABVC BioPharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Buyback Yield % compare to SGMO and SER?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #999999 out of 725 companies for Buyback Yield %. This places ABVC BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ABVC BioPharma and its competitors. ABVC BioPharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
ABVC BioPharma (ABVC) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. ABVC BioPharma's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Buyback Yield % is 0.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
29GF Score
Get the complete analysis for ABVC
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
